Brief: ARS Pharma To File Supplemental Application In U.S. For Lower Dose Neffy In Q3

ARS Pharmaceuticals

12/08/2024 14:25

Aug 12 (Reuters) - ARS Pharmaceuticals Inc  SPRY.O :
    * ARS PHARMACEUTICALS EXEC SAYS EXPECT TO FILE SUPPLEMENTAL
MARKETING APPLICATION IN U.S. FOR 1 MG DOSE OF NEFFY IN Q3 2024
- CONF CALL
    * ARS PHARMACEUTICALS EXEC SAYS EXPECT TO MAKE NEFFY
AVAILABLE IN
EUROPE LATER THIS YEAR
    * ARS PHARMACEUTICALS EXEC SAYS CO HAS ALREADY MANUFACTURED
"AT-RISK" LOTS OF NEFFY, IN PROCESS OF ASSEMBLING & PACKAGING
THOSE LOTS
    * ARS PHARMACEUTICALS EXEC REAFFIRMS PLANS TO LAUNCH NEFFY
IN U.S.
WITHIN ABOUT EIGHT WEEKS
    * ARS PHARMACEUTICALS EXEC SAYS CO EXPECTS TO ACHIEVE FULL
SCALE
PRODUCTION CAPACITY FOR NEFFY BY Q4 2024
    * ARS PHARMACEUTICALS EXEC SAYS "DON'T HAVE MUCH CONCERN"
ABOUT
PRODUCTION CAPACITY FOR NEFFY
    * ARS PHARMACEUTICALS EXEC SAYS RENAISSANCE PRODUCTION
FACILITY
CAN RAMP UP PRODUCTION OF NEFFY "VERY QUICKLY AND VERY
EFFECTIVELY" IF REQUIRED
    * ARS PHARMACEUTICALS EXEC SAYS CO "ALREADY TALKING TO THE
LARGEST
MANUFACTURER OF EMERGENCY KITS" FOR AIRLINES FOR ADOPTION OF
NEFFY

Further company coverage:  SPRY.O 

 ((Reuters.Briefs@thomsonreuters.com;))